TNF and cancer: One of the clinical trials investigating a TNF inhibitor (Etanercept, a recombinant fusion protein of TNF-α type II receptor) to treat cancer anorexia/weight loss syndrome in patients with solid tumor malignancies did not improve the outcomes of weight, appetite, or survival.